Myriad Genetics (MYGN) Assets Average (2011 - 2026)

Myriad Genetics (MYGN) has reported Assets Average for 16 consecutive years, with $690.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average fell 32.13% year-over-year to $690.2 million; the TTM figure through Mar 2026 stood at $690.2 million (down 32.13% YoY), while the FY2025 annual figure was $867.1 million, down 20.23% from the prior year.
• Assets Average eased to $690.2 million in Q1 2026 per MYGN's latest filing, from $717.4 million in the prior quarter.
• Across five years, Assets Average topped out at $1.3 billion in Q1 2022 and bottomed at $690.2 million in Q1 2026.
• Historically, Assets Average has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• Annual changes were most pronounced in 2023 — Assets Average retreated 3.55% — and 2025, when it sank 35.13%.
• Myriad Genetics' Assets Average stood at $1.2 billion in 2022, then dropped by 4.77% to $1.1 billion in 2023, then retreated by 8.13% to $1.1 billion in 2024, then plunged by 31.97% to $717.4 million in 2025, then declined by 3.79% to $690.2 million in 2026.
• Business Quant data shows MYGN's Assets Average at $690.2 million in Q1 2026, $717.4 million in Q4 2025, and $702.7 million in Q3 2025.